Contribute Try STAT+ Today

WASHINGTON — The Centers for Medicare and Medicaid Services proposed a major payment bump for hospitals administering the cutting-edge gene therapies known as CAR-T treatments late Monday.

It’s a direct response to longstanding criticisms from the pharmaceutical industry, patient advocates, and hospitals that said Medicare’s subpar reimbursement rates for the new therapies — which can have list prices upward of $450,000 per patient — forced hospitals to choose between losing money or declining to offer the therapies at all.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I hope Gilead and Novartis would agree to set the price for Yescarta and Kymrish as close as possible to say within $500 of each other to get around this average nonsense!

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy